Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease

Research output: Contribution to journalReview article

Abstract

Neuropsychiatric symptoms (NPS) are very common in neurodegenerative diseases and are a major contributor to disability and caregiver burden. There is accumulating evidence that NPS may be a prodrome and/or a "risk factor" of neurodegenerative diseases. The medications used to treat these symptoms in younger patients are not very effective in patients with neurodegenerative disease and may have serious side effects. An understanding of the neurobiology of NPS is critical for the development of more effective intervention strategies. Targeting these symptoms may also have implications for prevention of cognitive or motor decline. Molecular brain imaging represents a bridge between basic and clinical observations and provides many opportunities for translation from animal models and human post-mortem studies to in vivo human studies. Molecular brain imaging studies in Alzheimer's disease (AD) and Parkinson's disease (PD) are reviewed with a primary focus on positron emission tomography studies of NPS. Future directions for the field of molecular imaging in AD and PD to understand the neurobiology of NPS will be discussed.

Original languageEnglish (US)
Pages (from-to)157-170
Number of pages14
JournalNeuroscience and Biobehavioral Reviews
Volume49
DOIs
StatePublished - Feb 1 2015

Fingerprint

Molecular Imaging
Neurodegenerative Diseases
Parkinson Disease
Alzheimer Disease
Neurobiology
Neuroimaging
Positron-Emission Tomography
Caregivers
Animal Models

Keywords

  • Acetylcholine
  • Alzheimer's disease
  • Dopamine
  • Molecular imaging
  • Neuropsychiatric symptoms
  • Parkinson's disease
  • Positron emission tomography
  • Serotonin

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Cognitive Neuroscience
  • Behavioral Neuroscience

Cite this

Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease. / Hirao, Kentaro; Pontone, Gregory M; Smith, Gwenn.

In: Neuroscience and Biobehavioral Reviews, Vol. 49, 01.02.2015, p. 157-170.

Research output: Contribution to journalReview article

@article{f5d287f6a1d144b19a3f78e4c24ac4e8,
title = "Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease",
abstract = "Neuropsychiatric symptoms (NPS) are very common in neurodegenerative diseases and are a major contributor to disability and caregiver burden. There is accumulating evidence that NPS may be a prodrome and/or a {"}risk factor{"} of neurodegenerative diseases. The medications used to treat these symptoms in younger patients are not very effective in patients with neurodegenerative disease and may have serious side effects. An understanding of the neurobiology of NPS is critical for the development of more effective intervention strategies. Targeting these symptoms may also have implications for prevention of cognitive or motor decline. Molecular brain imaging represents a bridge between basic and clinical observations and provides many opportunities for translation from animal models and human post-mortem studies to in vivo human studies. Molecular brain imaging studies in Alzheimer's disease (AD) and Parkinson's disease (PD) are reviewed with a primary focus on positron emission tomography studies of NPS. Future directions for the field of molecular imaging in AD and PD to understand the neurobiology of NPS will be discussed.",
keywords = "Acetylcholine, Alzheimer's disease, Dopamine, Molecular imaging, Neuropsychiatric symptoms, Parkinson's disease, Positron emission tomography, Serotonin",
author = "Kentaro Hirao and Pontone, {Gregory M} and Gwenn Smith",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.neubiorev.2014.11.010",
language = "English (US)",
volume = "49",
pages = "157--170",
journal = "Neuroscience and Biobehavioral Reviews",
issn = "0149-7634",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease

AU - Hirao, Kentaro

AU - Pontone, Gregory M

AU - Smith, Gwenn

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Neuropsychiatric symptoms (NPS) are very common in neurodegenerative diseases and are a major contributor to disability and caregiver burden. There is accumulating evidence that NPS may be a prodrome and/or a "risk factor" of neurodegenerative diseases. The medications used to treat these symptoms in younger patients are not very effective in patients with neurodegenerative disease and may have serious side effects. An understanding of the neurobiology of NPS is critical for the development of more effective intervention strategies. Targeting these symptoms may also have implications for prevention of cognitive or motor decline. Molecular brain imaging represents a bridge between basic and clinical observations and provides many opportunities for translation from animal models and human post-mortem studies to in vivo human studies. Molecular brain imaging studies in Alzheimer's disease (AD) and Parkinson's disease (PD) are reviewed with a primary focus on positron emission tomography studies of NPS. Future directions for the field of molecular imaging in AD and PD to understand the neurobiology of NPS will be discussed.

AB - Neuropsychiatric symptoms (NPS) are very common in neurodegenerative diseases and are a major contributor to disability and caregiver burden. There is accumulating evidence that NPS may be a prodrome and/or a "risk factor" of neurodegenerative diseases. The medications used to treat these symptoms in younger patients are not very effective in patients with neurodegenerative disease and may have serious side effects. An understanding of the neurobiology of NPS is critical for the development of more effective intervention strategies. Targeting these symptoms may also have implications for prevention of cognitive or motor decline. Molecular brain imaging represents a bridge between basic and clinical observations and provides many opportunities for translation from animal models and human post-mortem studies to in vivo human studies. Molecular brain imaging studies in Alzheimer's disease (AD) and Parkinson's disease (PD) are reviewed with a primary focus on positron emission tomography studies of NPS. Future directions for the field of molecular imaging in AD and PD to understand the neurobiology of NPS will be discussed.

KW - Acetylcholine

KW - Alzheimer's disease

KW - Dopamine

KW - Molecular imaging

KW - Neuropsychiatric symptoms

KW - Parkinson's disease

KW - Positron emission tomography

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84996538837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996538837&partnerID=8YFLogxK

U2 - 10.1016/j.neubiorev.2014.11.010

DO - 10.1016/j.neubiorev.2014.11.010

M3 - Review article

VL - 49

SP - 157

EP - 170

JO - Neuroscience and Biobehavioral Reviews

JF - Neuroscience and Biobehavioral Reviews

SN - 0149-7634

ER -